tradingkey.logo

Sight Sciences Inc

SGHT
查看詳細走勢圖
5.870USD
+0.180+3.16%
收盤 02/06, 16:00美東報價延遲15分鐘
308.02M總市值
虧損本益比TTM

Sight Sciences Inc

5.870
+0.180+3.16%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.16%

5天

-6.53%

1月

-21.42%

6月

+59.51%

今年開始到現在

-25.98%

1年

+116.61%

查看詳細走勢圖

TradingKey Sight Sciences Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Sight Sciences Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力較大。當前估值合理,在醫療設備與耗材行業排名102/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為9.35。中期看,股價處於平穩狀態。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Sight Sciences Inc評分

相關信息

行業排名
102 / 205
全市場排名
274 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Sight Sciences Inc亮點

亮點風險
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
業績增長期
公司處於發展階段,最新年度總收入79.87M美元
估值低估
公司最新PE估值-6.57,處於3年歷史低位
機構減倉
最新機構持股25.69M股,環比減少9.84%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉3.89K股

分析師目標

基於 8 分析師
買入
評級
9.350
目標均價
+64.32%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Sight Sciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Sight Sciences Inc簡介

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
公司代碼SGHT
公司Sight Sciences Inc
CEOBadawi (Paul)
網址https://www.sightsciences.com/
KeyAI